Are CG-VAK Software & Exports Ltd latest results good or bad?

2 hours ago
share
Share Via
CG-VAK Software & Exports Ltd's latest Q4 FY26 results are concerning, showing a net profit of -₹0.02 crores and a year-on-year revenue decline of 3.26%, indicating significant operational challenges and a loss of market confidence. The company needs to address rising costs and declining margins to restore profitability.
CG-VAK Software & Exports Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported a net profit of -₹0.02 crores, marking a complete erosion of profitability compared to the previous year, which indicates a serious decline in financial performance. Revenue for the quarter was ₹19.01 crores, reflecting a slight quarter-on-quarter growth of 1.93% but a year-on-year decline of 3.26%.
The operating margin fell to 15.31%, the lowest in eight quarters, highlighting a concerning trend of margin compression despite stable revenue levels. This decline in profitability is attributed to rising employee costs, which consumed a larger portion of revenue, suggesting difficulties in achieving operational efficiency. Additionally, the company's effective tax rate surged to 116.67%, further complicating its financial position. For the full fiscal year FY26, CG-VAK's net sales showed a marginal decline, but the deterioration in Q4 raises questions about the sustainability of its performance. The company has also experienced a revision in its evaluation, reflecting the challenges it faces in maintaining profitability and operational stability. The absence of institutional investor interest and a significant drop in stock performance over various timeframes indicate a loss of market confidence in CG-VAK's ability to navigate the competitive IT services landscape effectively. Overall, the results underscore the need for immediate management attention to address the fundamental operational issues that have emerged, as the company seeks to restore profitability and improve its financial health.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News